Fol­low­ing a win for Baven­cio, Pfiz­er and Mer­ck KGaA con­tin­ue PD-L1 los­ing streak

Al­most two years ago Pfiz­er and Mer­ck KGaA con­ced­ed that their PD-L1 drug failed to sig­nif­i­cant­ly im­prove over­all sur­vival for gas­tric can­cer pa­tients in the third-line set­ting. We now know that Baven­cio doesn’t work as a first-line main­te­nance ther­a­py, ei­ther.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER